Background In the KEYNOTE-022 study, pembrolizumab with dabrafenib and trametinib (triplet)
improved progression-free survival (PFS) versus placebo with dabrafenib and trametinib …

Opinion statement The use of the cannabis plant by cancer patients has been rising significantly
in the past few years worldwide, primarily driven by public demand. There is an obvious …

Objectives Nivolumab has recently received regulatory approval as a 2nd-line treatment of
non-small cell lung cancer (NSCLC). The data regarding its effectiveness and safety in real …

The use of medical cannabis (MC) to treat cancer-related symptoms is rising. However,
there is a lack of long-term trials to assess the benefits and safety of MC treatment in this …

Background Chronic kidney disease patients are at increased risk of mortality with
cardiovascular diseases and infections as the two leading causes of death for end-stage kidney …

Cyclin-dependent kinase (CDK) 4/6 inhibitors given with endocrine therapy are standard of
care for the treatment of women with advanced hormone receptor (HR) positive and human …

Introduction: Immune checkpoint inhibitors have made a paradigm shift in the treatment of
non-small cell lung cancer (NSCLC). However, clinical response varies widely and robust …

Background: Imatinib is generally well tolerated in the treatment of advanced gastrointestinal
stromal tumors (GIST). Gastrointestinal vascular ectasia (GIVE) and gastric antral vascular …

Substantial evidence has accumulated showing that psychological distress affects immune
regulation, the response to cancer treatment, and survival. The effect of psychological …

Dear Editor On July 29, 2021, the Israeli Ministry of Health approved the third anti-Coronavirus
disease 2019 (COVID-19) vaccination (3rd-BNT162b2-booster-dose), leading to a sharp …